RE: Investors25 Sep 2021 16:46
Also this from the Q&A….
“Q9: In respect of cytokine activation in acute critical illness, this occurs in other conditions apart from Covid 19. Is there any evidence that your therapy may ameliorate this and prevent ARDS in other conditions? Are you able to give any more detail on the activities completed on the COVID tests? Can you tell us any more about the observations seen in human lung cells in the 1801 preclin work and is there read across here beyond Covid and indeed beyond lung conditions?
There is evidence in the literature that TYK2 inhibition may ameliorate the cytokine storm in other viral infections, such as influenza, and we are also undertaking some early preclinical studies with SDC-1801 in this area.
We will provide further details when the project is completed and the results are analysed, expected mid-year.“
Mid year ? We are now entering late year.